Spots Global Cancer Trial Database for erythropoietin
Every month we try and update this database with for erythropoietin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | NCT00381836 | Prostatic Neopl... Anemia | Darbepoetin Alf... | 18 Years - | University of Aarhus | |
| Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy | NCT01099202 | Leukemia | Procrit (epoeti... | - | M.D. Anderson Cancer Center | |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy | NCT00216541 | Anemia Neoplasms | epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation | NCT03010579 | Anemia Lymphoma Hematopoietic S... | erythropoietin iron supplement... | 18 Years - 65 Years | Peking University | |
| Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy | NCT00270127 | Anemia Cancer Neoplasm | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery | NCT00122720 | Colorectal Canc... | Darbepoetin Alf... | 18 Years - | Herning Hospital | |
| A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy | NCT00216541 | Anemia Neoplasms | epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer | NCT00269984 | Anemia | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | NCT00381836 | Prostatic Neopl... Anemia | Darbepoetin Alf... | 18 Years - | University of Aarhus | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia | NCT05931718 | Autoimmune Hemo... Immune Thromboc... Chronic Idiopat... Autoimmune Neut... Myelodysplastic... Cold Agglutinin... | cytokine essays NGS Fecal microbiom... Erythropoietin Luspatercept Thrombopoietin ... G-CSF | 18 Years - | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
| Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy | NCT00272662 | Chemotherapy In... Cancer | peginesatide | 18 Years - 80 Years | Affymax | |
| Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia | NCT05931718 | Autoimmune Hemo... Immune Thromboc... Chronic Idiopat... Autoimmune Neut... Myelodysplastic... Cold Agglutinin... | cytokine essays NGS Fecal microbiom... Erythropoietin Luspatercept Thrombopoietin ... G-CSF | 18 Years - | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
| Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes | NCT00003138 | Anemia Myelodysplastic... | Erythropoietin Filgrastim Transfusion | 18 Years - | Eastern Cooperative Oncology Group | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | NCT00270166 | Anemia Multiple Myelom... Lymphoma Breast Cancer Ovarian Cancer Carcinoma, Smal... Esophagus Cance... Prostate Cancer Neoplasm | epoetin alfa | 18 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy | NCT00270127 | Anemia Cancer Neoplasm | Epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | NCT00270101 | Anemia Multiple Myelom... | epoetin alfa | 40 Years - 80 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens | NCT05704894 | Anemia Neoplasms Chemotherapeuti... | Erythropoietin | 2 Years - 17 Years | Blau Farmaceutica S.A. | |
| Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy | NCT02860598 | Anemia Acute Myeloid L... | 18 Years - | Hospices Civils de Lyon | ||
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy | NCT00266617 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy | NCT00283465 | Anemia Neoplasm | Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations | NCT00624312 | Cancer | Procrit Placebo | 18 Years - | University of Louisville | |
| Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts | NCT00804050 | Myelodysplastic... | infusion A: rEP... B Infusion rEPO... | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | |
| A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients | NCT00254436 | Gastrointestina... Rectal Cancer | Procrit (epoeti... | 18 Years - | M.D. Anderson Cancer Center | |
| Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes | NCT00003138 | Anemia Myelodysplastic... | Erythropoietin Filgrastim Transfusion | 18 Years - | Eastern Cooperative Oncology Group | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS | NCT00520468 | Myelodysplastic... | Erythropoietin Cyclosporin A G-CSF Prednisone | - | M.D. Anderson Cancer Center | |
| Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | NCT00270049 | Anemia Leukemia, Lymph... Leukemia, Lymph... Cancer Neoplasms Quality of Life | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers | NCT00097747 | Anemia Chronic Kidney ... Chronic Renal F... Cancer | Placebo peginesatide | 18 Years - 40 Years | Affymax | |
| Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy | NCT00737893 | Prostate Cancer Erectile Dysfun... | Placebo Erythropoietin ... | 40 Years - 65 Years | Johns Hopkins University | |
| Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. | NCT01868477 | Low and Int 1-r... | Deferasirox DFX... Erythropoietin ... Deferasirox DFX... | 18 Years - | Novartis | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy | NCT00266617 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug | NCT00269997 | Anemia Neoplasms | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients | NCT00254436 | Gastrointestina... Rectal Cancer | Procrit (epoeti... | 18 Years - | M.D. Anderson Cancer Center | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | NCT00270049 | Anemia Leukemia, Lymph... Leukemia, Lymph... Cancer Neoplasms Quality of Life | epoetin alfa | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy | NCT02860598 | Anemia Acute Myeloid L... | 18 Years - | Hospices Civils de Lyon | ||
| Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus | NCT06135259 | Oral Lichen Pla... | erythropoietin Triamcinolone a... | 25 Years - 60 Years | Ain Shams University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
